

SAFETY DATA SHEET



Asenapine Formulation



Version 7.0 Revision Date: 30.09.2023 SDS Number: 690799-00017 Date of last issue: 04.04.2023
Date of first issue: 19.05.2016

Section 1: Identification

Product name : Asenapine Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address : 30 Hudson Street, 33rd floor
Jersey City, New Jersey, U.S.A 07302

Telephone : +1-551-430-6000

Emergency telephone number : +1-215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

Section 2: Hazard identification

GHS Classification

Acute toxicity (Oral) : Category 3

Acute toxicity (Inhalation) : Category 4

Reproductive toxicity : Category 2

Specific target organ toxicity - single exposure (Oral) : Category 1 (Central nervous system, Cardio-vascular system)

Specific target organ toxicity - repeated exposure (Oral) : Category 1 (Central nervous system)

Hazardous to the aquatic environment - acute hazard : Category 1

Hazardous to the aquatic environment - chronic hazard : Category 1

GHS label elements

Hazard pictograms :



Asenapine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
7.0	30.09.2023	690799-00017	Date of first issue: 19.05.2016

Signal word : Danger

Hazard statements : H301 Toxic if swallowed.
H332 Harmful if inhaled.
H361fd Suspected of damaging fertility. Suspected of damaging the unborn child.
H370 Causes damage to organs (Central nervous system, Cardio-vascular system) if swallowed.
H372 Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P261 Avoid breathing dust.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P271 Use only outdoors or in a well-ventilated area.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P301 + P310 + P330 IF SWALLOWED: Immediately call a POISON CENTER/ doctor. Rinse mouth.
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.
P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.
P391 Collect spillage.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
---------------	---------	-----------------------

SAFETY DATA SHEET



Asenapine Formulation



Version 7.0 Revision Date: 30.09.2023 SDS Number: 690799-00017 Date of last issue: 04.04.2023
Date of first issue: 19.05.2016

trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole maleate	85650-56-2	>= 30 -< 50
---	------------	-------------

Section 4: First-aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Call a physician or poison control centre immediately.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.
- Most important symptoms and effects, both acute and delayed : Toxic if swallowed.
Harmful if inhaled.
Suspected of damaging fertility. Suspected of damaging the unborn child.
Causes damage to organs if swallowed.
Causes damage to organs through prolonged or repeated exposure if swallowed.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

Section 5: Fire-fighting measures

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

Asenapine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
7.0	30.09.2023	690799-00017	Date of first issue: 19.05.2016

potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Hazchem Code : 2X

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air.
Add excess liquid to allow the material to enter into solution.
Soak up with inert absorbent material.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Asenapine Formulation

Version 7.0 Revision Date: 30.09.2023 SDS Number: 690799-00017 Date of last issue: 04.04.2023
Date of first issue: 19.05.2016

- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Keep in a cool, well-ventilated place.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Explosives

Section 8: Exposure controls/personal protection

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole maleate	85650-56-2	TWA	1 µg/m ³ (OEB 4)	Internal
Further information: Skin				
		Wipe limit	10 µg/100 cm ²	Internal

- Engineering measures : Containment technologies suitable for controlling compounds

Asenapine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
7.0	30.09.2023	690799-00017	Date of first issue: 19.05.2016

are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

Personal protective equipment

Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Section 9: Physical and chemical properties

Appearance	:	powder
Colour	:	white to off-white
Odour	:	odourless
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable

SAFETY DATA SHEET



Asenapine Formulation



Version 7.0 Revision Date: 30.09.2023 SDS Number: 690799-00017 Date of last issue: 04.04.2023
Date of first issue: 19.05.2016

Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Particle size	:	No data available

Section 10: Stability and reactivity

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents

Asenapine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
7.0	30.09.2023	690799-00017	Date of first issue: 19.05.2016

Hazardous decomposition products : No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Toxic if swallowed.
Harmful if inhaled.

Product:

Acute oral toxicity : Acute toxicity estimate: 238.4 mg/kg
Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: 1.08 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: Calculation method

Components:

trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole maleate:

Acute oral toxicity : LD50 (Rat): 110 - 178 mg/kg
LD50 (Dog): > 200 mg/kg
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 0.5 - 2 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist

Acute toxicity (other routes of administration) : LD50 (Rat): > 200 mg/kg
Application Route: Intravenous
Target Organs: Central nervous system
Remarks: No mortality observed at this dose.

Skin corrosion/irritation

Not classified based on available information.

Components:

trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole maleate:

Remarks : No data available

Asenapine Formulation

Version 7.0 Revision Date: 30.09.2023 SDS Number: 690799-00017 Date of last issue: 04.04.2023
Date of first issue: 19.05.2016

Serious eye damage/eye irritation

Not classified based on available information.

Components:

**trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole ma-
leate:**

||Remarks : No data available

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

**trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole ma-
leate:**

||Species : Guinea pig
||Result : Not a skin sensitizer.

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:

**trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole ma-
leate:**

||Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Mouse Lymphoma
Result: negative

Test Type: sister chromatid exchange assay
Result: negative

Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: negative

||Genotoxicity in vivo : Test Type: Micronucleus test
Species: Rat
Application Route: Oral
Result: negative

Asenapine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
7.0	30.09.2023	690799-00017	Date of first issue: 19.05.2016

Carcinogenicity

Not classified based on available information.

Components:**trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole maleate:**

Species	:	Mouse
Application Route	:	Subcutaneous
Exposure time	:	89 - 98 weeks
Result	:	negative

Species	:	Rat
Application Route	:	Subcutaneous
Exposure time	:	100 - 106 weeks
Result	:	negative

Reproductive toxicity

Suspected of damaging fertility. Suspected of damaging the unborn child.

Components:**trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole maleate:**

Effects on fertility	:	Test Type: One-generation reproduction toxicity study
		Species: Rat
		Application Route: Oral
		Fertility: LOAEL: 1.0 mg/kg body weight
		Symptoms: Reduced maternal body weight gain, Reduced offspring weight gain, Effects on fertility, Effects on F1 offspring
	:	Result: Embryotoxic effects and adverse effects on the offspring were detected.

Effects on foetal development	:	Test Type: Embryo-foetal development
		Species: Rabbit
		Application Route: Oral
	:	Developmental Toxicity: LOAEL: 30 mg/kg body weight
	:	Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, No teratogenic effects

	:	Test Type: Embryo-foetal development
		Species: Rabbit
		Application Route: Intravenous injection
	:	Developmental Toxicity: NOAEL: 0.626 mg/kg body weight
	:	Result: No teratogenic effects

Reproductive toxicity - Assessment	:	Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.
------------------------------------	---	--

Asenapine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
7.0	30.09.2023	690799-00017	Date of first issue: 19.05.2016

||

STOT - single exposure

Causes damage to organs (Central nervous system, Cardio-vascular system) if swallowed.

Components:

trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole maleate:

Exposure routes	: Oral
Target Organs	: Central nervous system, Cardio-vascular system
Assessment	: Causes damage to organs.

STOT - repeated exposure

Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

Components:

trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole maleate:

Exposure routes	: Ingestion
Target Organs	: Central nervous system
Assessment	: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:**

trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole maleate:

Species	: Rat
LOAEL	: 0.6 mg/kg
Application Route	: Oral
Exposure time	: 52 Weeks
Target Organs	: Central nervous system
Symptoms	: constriction of pupils

Species	: Rat
LOAEL	: 0.1 mg/kg
Application Route	: Intravenous
Exposure time	: 14 Weeks
Symptoms	: constriction of pupils, Lachrymation

Species	: Rat
LOAEL	: 0.5 mg/kg
Application Route	: Subcutaneous
Exposure time	: 13 Weeks
Target Organs	: Central nervous system

Species	: Dog
---------	-------

Asenapine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
7.0	30.09.2023	690799-00017	Date of first issue: 19.05.2016

LOAEL	:	> 1.25 mg/kg
Application Route	:	Oral
Exposure time	:	13 - 52 Weeks
Target Organs	:	Central nervous system
Symptoms	:	constriction of pupils, Tremors, Irritability

Aspiration toxicity

Not classified based on available information.

Components:

**trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole ma-
leate:**

|| Not applicable

Experience with human exposure**Components:**

**trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole ma-
leate:**

Ingestion	:	Symptoms: restlessness, Drowsiness, Dizziness, decrease in heart rate, hypotension
-----------	---	--

Section 12: Ecological information**Ecotoxicity****Components:**

**trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole ma-
leate:**

Toxicity to fish	:	LC50 (Cyprinus carpio (Carp)): 0.53 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): 0.27 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 0.084 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	:	1
Toxicity to fish (Chronic toxicity)	:	NOEC (Pimephales promelas (fathead minnow)): 0.04 mg/l Exposure time: 21 d
Toxicity to daphnia and other	:	NOEC (Daphnia magna (Water flea)): 0.00086 mg/l

SAFETY DATA SHEET



Asenapine Formulation



Version 7.0 Revision Date: 30.09.2023 SDS Number: 690799-00017 Date of last issue: 04.04.2023
Date of first issue: 19.05.2016

aquatic invertebrates (Chronic toxicity) Exposure time: 21 d
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity) : 100

Toxicity to microorganisms : EC50: 37 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 10 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Persistence and degradability

No data available

Bioaccumulative potential

Components:

trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole maleate:

Bioaccumulation : Species: Cyprinus carpio (Carp)
Bioconcentration factor (BCF): 2,424

Partition coefficient: n-octanol/water : log Pow: 4.9

Mobility in soil

No data available

Other adverse effects

No data available

Section 13: Disposal considerations

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG

UN number : UN 2811
Proper shipping name : TOXIC SOLID, ORGANIC, N.O.S.

Asenapine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
7.0	30.09.2023	690799-00017	Date of first issue: 19.05.2016

|| (trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole maleate)

Class : 6.1
Packing group : III
Labels : 6.1
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 2811
Proper shipping name : Toxic solid, organic, n.o.s.

|| (trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole maleate)

Class : 6.1
Packing group : III
Labels : Toxic
Packing instruction (cargo aircraft) : 677
Packing instruction (passenger aircraft) : 670

IMDG-Code

UN number : UN 2811
Proper shipping name : TOXIC SOLID, ORGANIC, N.O.S.

|| (trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole maleate)

Class : 6.1
Packing group : III
Labels : 6.1
EmS Code : F-A, S-A
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**NZS 5433**

UN number : UN 2811
Proper shipping name : TOXIC SOLID, ORGANIC, N.O.S.

|| (trans-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole maleate)

Class : 6.1
Packing group : III
Labels : 6.1
Hazchem Code : 2X
Marine pollutant : yes

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

Asenapine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
7.0	30.09.2023	690799-00017	Date of first issue: 19.05.2016

Section 15: Regulatory information**Safety, health and environmental regulations/legislation specific for the substance or mixture****HSNO Approval Number**

HSR100425 Pharmaceutical Active Ingredients Group Standard

HSW Controls

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

Section 16: Other information

Revision Date : 30.09.2023

Further informationSources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviations

AIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Or-

SAFETY DATA SHEET



Asenapine Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
7.0	30.09.2023	690799-00017	Date of first issue: 19.05.2016

ganisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN